转移性黑色素瘤患者接受伊匹木单抗治疗后,18F-FDG PET/CT上新发病灶的绝对数量比SUV变化更能预测临床反应
本研究以41例接受伊匹木单抗治疗的转移性黑色素瘤患者为对象,在治疗前后行18F-FDG PET/CT,以临床反应为参照,分析新发18F-FDG高摄取病灶数量、功能大小及SUV变化。结果显示,治疗后PET/CT上新发高摄取病灶≥4个预测临床获益的敏感度为84%、特异度为100%,SUV变化与临床反应无关,据此提出PERCIMT标准。
要点
- 治疗后PET/CT新发18F-FDG高摄取病灶≥4个预测临床获益的敏感度84%、特异度100%。
- 病灶功能直径越大,预测所需的病灶数量越少:大于1.0 cm者3个、大于1.5 cm者2个。
- 治疗后SUV变化与临床反应无相关性。
核心结论
- 治疗后PET/CT上新发18F-FDG高摄取病灶≥4个可可靠提示伊匹木单抗治疗失败。
- 新发病灶的功能大小在预测临床反应中起重要作用。
- 作者建议在更大规模队列中验证上述结果。
研究设计与样本
- 最终分析队列为41例接受伊匹木单抗治疗的转移性黑色素瘤患者,治疗前后均行18F-FDG PET/CT。
- 先确定最佳临床反应,再独立回顾PET/CT,分析新发18F-FDG高摄取病灶的数量和功能大小以及治疗后SUV变化。
主要发现
- 患者治疗后中位观察时间为21.4个月(范围6.3–41.9个月)。
- 按临床反应分为临床获益组31例(含疾病稳定、部分缓解和完全缓解)与无临床获益组10例(含疾病进展)。
- 以治疗后PET/CT新发18F-FDG高摄取病灶≥4个为阈值,预测临床获益的敏感度为84%、预测无临床获益的特异度为100%。
- 该阈值在新发病灶功能直径较大时更低:大于1.0 cm的新发病灶为3个,大于1.5 cm的新发病灶为2个。
- 治疗后SUV变化与临床反应无相关性。
关键数值与推荐
- 基于上述结果提出PET Response Evaluation Criteria for Immunotherapy(PERCIMT)。
- 新发18F-FDG高摄取病灶≥4个:预测临床获益敏感度84%、预测无临床获益特异度100%。
- 新发病灶大于1.0 cm者阈值3个,大于1.5 cm者阈值2个。
临床怎么用
- 作者认为治疗后PET/CT上新发18F-FDG高摄取病灶≥4个可可靠提示伊匹木单抗治疗失败。
- 作者认为新发病灶的功能大小在预测临床反应中起重要作用。
- 作者建议在更大规模患者队列中验证这些结果。
局限性
- 作者指出需要在更大规模患者队列中验证这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evaluation of response to immunotherapy is a matter of debate. The aim of the present study was to evaluate the response of metastatic melanoma to treatment with ipilimumab by means of 18F-FDG PET/CT, using the patients' clinical response as reference. METHODS: The final cohort included in the analyses consisted of 41 patients with metastatic melanoma who underwent 18F-FDG PET/CT before and after administration of ipilimumab. After determination of the best clinical response, the PET/CT scans were reviewed and a separate independent analysis was performed, based on the number and functional size of newly emerged 18F-FDG-avid lesions, as well as on the SUV changes after therapy. RESULTS: The median observation time of the patients after therapy was 21.4 months (range 6.3-41.9 months). Based on their clinical response, patients were dichotomized into those with clinical benefit (CB) and those without CB (No-CB). The CB group (31 patients) included those with stable disease, partial remission and complete remission, and the No-CB group (10 patients) included those with progressive disease. The application of a threshold of four newly emerged 18F-FDG-avid lesions on the posttherapy PET/CT scan led to a sensitivity (correctly predicting CB) of 84% and a specificity (correctly predicting No-CB) of 100%. This cut-off was lower for lesions with larger functional diameters (three new lesions larger than 1.0 cm and two new lesions larger than 1.5 cm). SUV changes after therapy did not correlate with clinical response. Based on these findings, we developed criteria for predicting clinical response to immunotherapy by means of 18F-FDG PET/CT (PET Response Evaluation Criteria for Immunotherapy, PERCIMT). CONCLUSION: Our results show that a cut-off of four newly emerged 18F-FDG-avid lesions on posttherapy PET/CT gives a reliable indication of treatment failure in patients under ipilimumab treatment. Moreover, the functional size of the new lesions plays an important role in predicting the clinical response. Validation of these results in larger cohorts of patients is warranted.
引用
- Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2017. PMID: 29124281. doi:10.1007/s00259-017-3870-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。